Therefore, the GLP-1 and GIP/GLP-1 receptor agonists in this clinical setting have value in their weight reduction potential and glucose metabolism normalization as well as cardiovascular risk reduction and could even progress to first-line therapy for obstructive sleep apnea [73]. Here, GIP is linked to obstructive sleep apnea syndrome.